Suppliers

Lonza Small Molecules

Lonza Small Molecules

At Lonza Small Molecules, our connected experts work together to provide contract development and manufacturing services, helping pharma and small biotech companies deliver their medicines to patients in need. From the earliest stages of discovery to the final drug product, we can simplify your outsourcing experience with our reliable, timely service, anticipating risks and solving problems.

Whether you are developing a pioneering therapy or creating a new oral solid dosage form, Lonza is the only CDMO partner you need. Throughout your molecule’s journey from early development to commercial product, we work as one.

Latest content from Lonza Small Molecules

show more

Lonza de-risks drug development through PBPK

Paid for and in partnership with Lonza Small Molecules

The opportunity to de-risk drug development through PBPK

No company wants to progress a molecule through to the clinic only to suffer a bad readout. PBPK modeling services allow companies to predict what absorption challenges may arise in trials, and plan ways to mitigate them.

Related resources

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...